Trial Profile
Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD03 Applied During AFFiRiS 005A [EXTENSION OF 700195864]
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Affitope AD03 (Primary) ; Alum
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors AFFiRiS
- 20 Mar 2014 New trial record